Literature DB >> 20579536

The long and winding road to warfarin pharmacogenetic testing.

Geoffrey S Ginsburg, Deepak Voora.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20579536     DOI： 10.1016/j.jacc.2010.04.006

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN： 0735-1097            Impact factor:   24.094


× No keyword cloud information.
  14 in total

Review 1.  Bridging the efficacy-effectiveness gap: a regulator's perspective on addressing variability of drug response.

Authors:  Hans-Georg Eichler; Eric Abadie; Alasdair Breckenridge; Bruno Flamion; Lars L Gustafsson; Hubert Leufkens; Malcolm Rowland; Christian K Schneider; Brigitte Bloechl-Daum
Journal:  Nat Rev Drug Discov       Date:  2011-07-01       Impact factor: 84.694

2.  Statistical Optimization of Pharmacogenomics Association Studies: Key Considerations from Study Design to Analysis.

Authors:  Benjamin J Grady; Marylyn D Ritchie
Journal:  Curr Pharmacogenomics Person Med       Date:  2011-03-01

Review 3.  Role of pharmacogenomics in the management of traditional and novel oral anticoagulants.

Authors:  Larisa H Cavallari; Jaekyu Shin; Minoli A Perera
Journal:  Pharmacotherapy       Date:  2011-12       Impact factor: 4.705

4.  CYP2C9 and VKORC1 polymorphisms influence warfarin dose variability in patients on long-term anticoagulation.

Authors:  Paulo Caleb Junior Lima Santos; Carla Luana Dinardo; Isolmar Tadeu Schettert; Renata Alonso Gadi Soares; Liz Kawabata-Yoshihara; Isabela Martins Bensenor; José Eduardo Krieger; Paulo Andrade Lotufo; Alexandre Costa Pereira
Journal:  Eur J Clin Pharmacol       Date:  2012-09-19       Impact factor: 2.953

Review 5.  Genotype-based dosing algorithms for warfarin therapy: data review and recommendations.

Authors:  Eric G Johnson; Benjamin D Horne; John F Carlquist; Jeffrey L Anderson
Journal:  Mol Diagn Ther       Date:  2011-10-01       Impact factor: 4.074

6.  A pharmacogenetic versus a clinical algorithm for warfarin dosing.

Authors:  Stephen E Kimmel; Benjamin French; Scott E Kasner; Julie A Johnson; Jeffrey L Anderson; Brian F Gage; Yves D Rosenberg; Charles S Eby; Rosemary A Madigan; Robert B McBane; Sherif Z Abdel-Rahman; Scott M Stevens; Steven Yale; Emile R Mohler; Margaret C Fang; Vinay Shah; Richard B Horenstein; Nita A Limdi; James A S Muldowney; Jaspal Gujral; Patrice Delafontaine; Robert J Desnick; Thomas L Ortel; Henny H Billett; Robert C Pendleton; Nancy L Geller; Jonathan L Halperin; Samuel Z Goldhaber; Michael D Caldwell; Robert M Califf; Jonas H Ellenberg
Journal:  N Engl J Med       Date:  2013-11-19       Impact factor: 91.245

Review 7.  Genomics and drug response.

Authors:  Liewei Wang; Howard L McLeod; Richard M Weinshilboum
Journal:  N Engl J Med       Date:  2011-03-24       Impact factor: 91.245

8.  Cost-effectiveness of cytochrome P450 2C19 genotype screening for selection of antiplatelet therapy with clopidogrel or prasugrel.

Authors:  Emily S Reese; C Daniel Mullins; Amber L Beitelshees; Eberechukwu Onukwugha
Journal:  Pharmacotherapy       Date:  2012-04       Impact factor: 4.705

Review 9.  Clopidogrel and warfarin pharmacogenetic tests: what is the evidence for use in clinical practice?

Authors:  Mohamed H A Shahin; Julie A Johnson
Journal:  Curr Opin Cardiol       Date:  2013-05       Impact factor: 2.161

10.  A Framework for Prioritizing Research Investments in Precision Medicine.

Authors:  Anirban Basu; Josh J Carlson; David L Veenstra
Journal:  Med Decis Making       Date:  2015-10-26       Impact factor: 2.583
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.